# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number 10523268 Filing Date 2005-07-07 First Named Inventor John Schenk Art Unit 1632 Examiner Name Marcia Stephens Noble Attorney Docket Number XY-Low Pressure USNP

			Remove			
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	US501749	А	1991-05-21	Grooth et al.	
	2	5934885		1999-08-10	Farrell et al.	
	3	7195920		2007-03-27	Seidel et al.	
	4	5559032		1996-09-24	Pomeroy et al.	
	5	3756459		1973-09-04	Bannister	
If you wish	n to ac	dd additional U.S. Paten		·	ease click the Add button.	Add
		I	U.S.P	ATENT APPLIC	CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20050064383	A1	2005-03-24	Bashkin et al.	

( Not for submission under 37 CFR 1.99)

Application Number		10523268		
Filing Date		2005-07-07		
First Named Inventor	John	Schenk		
Art Unit		1632		
Examiner Name	Marci	a Stephens Noble		
Attorney Docket Numb	er	XY-I ow Pressure USNP		

	2	20060281176	A1	2006-12	?-14	Seidel et al.					
	3	20070026378	A1	2007-02	2-01	Schenk					
	4	20070026379	A1	2007-02	?-01	Seidel et al					
	5	20060118167	A1	2006-06	5-08	Neas et al.					
	6	20050011582	A1	2005-01	-20	Haug					
If you wis	n to ac	dd additional U.S. Publi	•	•		•		d butto			
				FOREIG	ON PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patentee Applicant of cited Document		Pages,Colun where Relev Passages or Figures Appe	ant Relevant	<b>T</b> 5
	1	2003020877	WO		A2	2002-08-15	Pharmacia Corp. (d Monsanto Compan				
	2	2007/016090	WO		A2	2007-02-08	XY, Inc.				
	3	0140616	EP			1985-05-08	Technicon Insrume Corp.	nts			
	4	1991/05236	WO			1991-04-18	Aerometrics, Inc.				

( Not for submission under 37 CFR 1.99)

Application Number		10523268		
Filing Date		2005-07-07		
First Named Inventor	John	Schenk		
Art Unit		1632		
Examiner Name	Marci	a Stephens Noble		
Attorney Docket Numb	er	XY-Low Pressure USNP		

	5	2002041906	WO	A2	2001-11-21	Pharmacia Corp. (c/o Monsanto Company)			
	6	2006060770	WO	A2	2006-08-06	XY, Inc.			
If you wisl	h to ac	dd additional Foreign Pa	atent Document	citation	information pl	lease click the Add buttor	1 Add		
			NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove		
Examiner Initials*	Cite No		nal, serial, symp	osium,	catalog, etc), o	the article (when appropi date, pages(s), volume-is		T5	
	1	Hanania, E. G, et al. A novel Automated Method of Scanning Cytometry and Laser-Induced Necrosis Applied to Tumor Cell Purging, Blood. 15 November 1999, Vol. 94, No. 10, suppl 1 part 1							
	2	Purdy, P. H. et al., Effect of Adding Cholesterol to Bull Sperm Membranes on Sperm Capacitation, the Acrosome Reaction, and Fertility, Biology of Reproduction 71, 522-527 (2004)							
	3	Purdy, P. H. et al., Effect of cholesterol-loaded cyclodextrin on the cryosurvival of bull sperm, Cryobiology 48 (2004) 36-45							
	4	Moce E., et al., Cholesterol-loaded cyclodextrins added to fresh bull ejaculates improve sperm cryosurvival, J. Anim. Sci, 2006, 84:826-833							
	5	Ereth, B.A., et al. Integration of Early Weaning and Sexed Semen into a Single-Calf Heifer System to Increase Value of Non-Replacement Heifers; Proceedings, Western Section, American Society of Animal Science, Vol. 51,441-443, June 2000							
	6	Ereth, B.A., et al. Integration of Early Weaning and Sexed Semen into a Single-Calf Heifer System to Increase Value of Non-Replacement Heifers; Abstract Only, Journal of Animal Science, Vol. 78, Supplement 2, 2000							
	7	Bavister, B.D. et al., The effects of Sperm Extracts and Energy Sources on the Motility and Acromosome Reaction of hamster Spermatozoa in vitero; Biology of Reporduction 16, 228-237 (1997)							

( Not for submission under 37 CFR 1.99)

Application Number		10523268		
Filing Date		2005-07-07		
First Named Inventor	John	Schenk		
Art Unit		1632		
Examiner Name	Marci	a Stephens Noble		
Attorney Docket Numb	er	XY-Low Pressure USNP		

	8		Fattouh, El-S.M. et al., Effect of Caffine on the Post-Thaw Motility of Buffalo Spermatozoa; Theriogenology, July 1991, vol. 36 No. 1							
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add									
	EXAMINER SIGNATURE									
Examiner	Signa	ture		Date Considered						
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									
<sup>1</sup> See Kind Codes of USPTO Patent Documents at <a href="https://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.										

( Not for submission under 37 CFR 1.99)

Application Number		10523268		
Filing Date		2005-07-07		
First Named Inventor	John	Schenk		
Art Unit		1632		
Examiner Name	Marci	a Stephens Noble		
Attorney Docket Numb	er	XY-Low Pressure USNP		

Plea	Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):								
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).								
OR	1								
	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).								
	See attached ce	rtification statement.							
×	Fee set forth in 3	37 CFR 1.17 (p) has been submitted herewith	1.						
	None								
1	SIGNATURE  A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.								
Sigr	Signature /Nicole A. Ressue/ Date (YYYY-MM-DD) 2007-03-29								
Nan	Name/Print Nicole A. Ressue Registration Number 48665								
pub 1.14	lic which is to file it.  This collection it.	rmation is required by 37 CFR 1.97 and 1.98 (and by the USPTO to process) an application is estimated to take 1 hour to complete, inclued USPTO. Time will vary depending upon the	on. Confidentiality is gover ding gathering, preparing	rned by 35 U.S.C. 122 and 37 CFR and submitting the completed					

require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria**,

**CERTIFICATION STATEMENT** 

VA 22313-1450.

#### **Privacy Act Statement**

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a
  court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement
  negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
  - 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.